Description: DICE Therapeutics, Inc. is a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. It designs and develops therapies in immunology for patients with chronic diseases. The company's lead therapeutic candidate, S011806, is an oral antagonist of the pro-inflammatory signaling molecule, interleukin-17 (IL-17), which is a validated drug target implicated in various immunology indications. It is also developing oral therapeutic candidates targeting a4Ã7 integrin and aVÃ1/aVÃ6 integrin for the treatment of inflammatory bowel disease and idiopathic pulmonary fibrosis. The company was founded in 2013 and is headquartered in South San Francisco, California.
Home Page: www.dicemolecules.com
DICE Technical Analysis
279 East Grand Avenue
South San Francisco,
CA
94080
United States
Phone:
650 566 1402
Officers
| Name | Title |
|---|---|
| Dr. J. Kevin Judice Ph.D. | Founder, CEO & Director |
| Mr. Scott Robertson | Chief Bus. & Financial Officer |
| Dr. Timothy Lu M.D., Ph.D. | Chief Medical Officer |
| Dr. John R. Jacobsen Ph.D. | Chief Scientific Officer |
| Ms. Mary Riley J.D. | Gen. Counsel |
| Mr. Venkat Thalladi Ph.D. | Sr. VP of CMC |
| Mr. Paul Fatheree | Sr. VP of Medicinal Chemistry |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 11.3409 |
| Price-to-Book MRQ: | 5.9124 |
| Price-to-Sales TTM: | 699.0015 |
| IPO Date: | 2021-09-15 |
| Fiscal Year End: | December |
| Full Time Employees: | 65 |